Agree. With 45-50 dead, that data point alone will show one way or the other, and we should have enough evidence to build a compelling case. I would think it is well worth the gamble if LL is down at 10% and the alternative is to keep trudging along enrolling until the EOY.

The rest of the call was a mess. Nothing from NASDAQ, very slow cancer enrollment, and two steps back on the HIV BLA. However, the CD12 still has the potential to push us to the top of the COVID race in the next two weeks.